Supernus Pharmaceuticals, Inc.
SUPN
$44.88
$1.563.60%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 1,131.09% | 499.24% | 5,512.84% | 133.05% | -87.91% |
| Total Depreciation and Amortization | -5.07% | -5.83% | -5.24% | -0.94% | 1.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -100.00% | -100.00% |
| Total Other Non-Cash Items | 33.97% | -23.31% | -41.15% | 119.65% | -12.33% |
| Change in Net Operating Assets | -70.93% | -191.45% | 77.54% | 117.93% | 151.74% |
| Cash from Operations | 20.79% | 63.56% | 54.79% | 84.12% | 116.11% |
| Capital Expenditure | -180.52% | -54.32% | -31.58% | 17.50% | 25.78% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 37.67% | -351.94% | -170.24% | -184.72% | -177.30% |
| Cash from Investing | 36.96% | -345.10% | -170.65% | -185.05% | -177.81% |
| Total Debt Issued | -- | -- | -- | -100.00% | -100.00% |
| Total Debt Repaid | -- | -- | -- | 100.00% | 100.00% |
| Issuance of Common Stock | 144.60% | 93.28% | 125.54% | 9.30% | -54.48% |
| Repurchase of Common Stock | -106.01% | -63.47% | -36.43% | 13.17% | -126.57% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -381.15% | 97.74% | 103.06% | 101.87% | 101.05% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 238.25% | 113.15% | 68.32% | -283.55% | 118.41% |